OpenEvidence raises $210M, unveils AI agents built for advanced medical research

AI medical search engine OpenEvidence has closed a $210 million Series B funding round, co-led by Google Ventures and Kleiner Perkins, elevating its valuation to $3.5 billion. This significant capital infusion validates OpenEvidence's rapid market traction, evidenced by claims of over 40% U.S. physician adoption and supporting 8.5 million monthly clinical consultations, and its differentiated strategy of leveraging exclusive content partnerships with leading medical journals and advanced AI tools like DeepConsult to deliver precise, evidence-based medical information, addressing critical needs in healthcare efficiency and clinician support.

Analysis

OpenEvidence has secured a significant $210 million Series B funding round, elevating its valuation to $3.5 billion and signaling strong investor confidence from prominent firms like Google Ventures, Kleiner Perkins, and Sequoia. This validation is underpinned by exceptional growth metrics, including a claimed adoption rate by over 40% of U.S. physicians and a dramatic increase in usage from 358,000 physician consultations in one month a year ago to over 8.5 million per month currently. The company's strategic moat is built on two pillars: exclusive content partnerships with premier medical publishers like the American Medical Association and The New England Journal of Medicine, and the founder's proven track record. CEO Daniel Nadler, who previously sold Kensho Technologies to S&P Global for $700 million, is positioning OpenEvidence to win by controlling proprietary, high-value content, a strategy he likens to differentiation in the commoditized streaming service market. The launch of DeepConsult, an advanced AI research agent, further extends its product offering beyond rapid search to deep synthesis, addressing critical issues of clinician burnout and information overload within the U.S. healthcare system.

Key Decisions for Investors

• Given OpenEvidence's rapid market penetration and defensible content strategy, investors should assess the competitive risk for other health-tech and medical information platforms that rely on publicly available data.
• The company's valuation is heavily reliant on its explosive user growth and exclusive content partnerships; monitoring the durability of these partnerships and the continued momentum of new clinician registrations is critical for validating its long-term trajectory.
• Considering the founder's prior successful exit of Kensho to S&P Global, a future acquisition by a major technology, healthcare, or financial information conglomerate is a highly plausible exit scenario, making OpenEvidence a key private entity to watch for M&A signals in the AI and healthcare sectors.